Antigen-antibody interaction

Summary

Antigen-antibody interaction, or antigen-antibody reaction, is a specific chemical interaction between antibodies produced by B cells of the white blood cells and antigens during immune reaction. The antigens and antibodies combine by a process called agglutination. It is the fundamental reaction in the body by which the body is protected from complex foreign molecules, such as pathogens and their chemical toxins. In the blood, the antigens are specifically and with high affinity bound by antibodies to form an antigen-antibody complex. The immune complex is then transported to cellular systems where it can be destroyed or deactivated. The first correct description of the antigen-antibody reaction was given by Richard J. Goldberg at the University of Wisconsin in 1952. It came to be known as "Goldberg's theory" (of antigen-antibody reaction). There are several types of antibodies and antigens, and each antibody is capable of binding only to a specific antigen. The specificity of the b

Official source

https://en.wikipedia.org/wiki/Antigen-antibody_interaction

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (12)

Related publications

Related people (1)

Related people

Related units

Related concepts (1)

Related concepts

Related courses (7)

Related courses

Related lectures (9)

Related lectures

Related publications (12)

Self-interaction chromatography

Caroline Mingard

EPFL2006

Dectin-2 is a C-type lectin involved in the recognition of several pathogens such as Aspergillus fumigatus, Candida albicans, Schistosoma mansonii, and Mycobacterium tuberculosis that triggers Th17 immune responses. Identifying pathogen ligands and understanding the molecular basis of their recognition is one of the current challenges. Purified M. tuberculosis mannose-capped lipoarabinomannan (ManLAM) was shown to induce signaling via Dectin-2, an activity that requires the (alpha 1 -> 2)-linked mannosides forming the caps. Here, using isogenic M. tuberculosis mutant strains, we demonstrate that ManLAM is a bona fide and actually the sole ligand mediating bacilli recognition by Dectin-2, although M. tuberculosis produces a variety of cell envelope mannoconjugates, such as phosphatidyl-myo-inositol hexamannosides, lipomannan or manno(lipo)proteins, that bear (alpha 1 -> 2)-linked mannosides. In addition, we found that Dectin-2 can recognize lipoglycans from other bacterial species, such as Saccharotrix aerocolonigenes or the human opportunistic pathogen Tsukamurella paurometabola, suggesting that lipoglycans are prototypical Dectin-2 ligands. Finally, from a structure/function relationship perspective, we show, using lipoglycan variants and synthetic mannodendrimers, that dimannoside caps and multivalent interaction are required for ligand binding to and signaling via Dectin-2. Better understanding of the molecular basis of ligand recognition by Dectin-2 will pave the way for the rational design of potent adjuvants targeting this receptor.

NATURE PUBLISHING GROUP2018

PROBLEM TO BE SOLVED: To provide a novel polypeptide derived from bee venom and a method of use thereof, and also to provide a pharmaceutical composition useful for modulating bee immune responses to pollens. ;SOLUTION: The invention provides a substantially pure polypeptide comprising an amino acid sequence at least 70% identical, and more preferably at least 90% identical, to the amino acid sequence of an Api m 6 polypeptide. The invention further provides an antibody binding to an Api m 6 protein, and a composition comprising polypeptide fragments of the Api m 6 protein. ;COPYRIGHT: (C)2011,JPO&INPIT

2011